At-home genetic testing kits promised something genuinely radical when they first reached the mainstream consumer market in the mid-2000s: the ability to spit in a tube, mail it off, and receive a window into your own DNA, covering everything from ancestry to disease risk to inherited traits. For a few hundred dollars, consumers could access information that had previously required a clinical referral, a geneticist, and often a substantial wait. Millions of people took up the offer. By 2022, usage of direct-to-consumer genetic testing in the United States had more than doubled from 19% to 40% of adults in just two years.
Then, in March 2025, 23andMe, the company that did more than any other to popularise consumer genetic testing, filed for Chapter 11 bankruptcy. A company once valued at $6 billion was sold off in a court-supervised auction for $256 million to Regeneron Pharmaceuticals, a pharmaceutical company with its own interest in the genetic data of millions of customers. The collapse of the industry’s most recognisable brand raises an uncomfortable question that this essay addresses directly: are at-home genetic testing kits genuinely useful tools for consumers, or have they been selling a kind of false hope, packaged as scientific insight, to people who do not fully understand what the results can and cannot tell them?
The Case For: Genuine Utility in Specific Applications
The strongest case for at-home genetic testing rests on its most popular use case: ancestry. Research consistently shows that ancestry testing is the primary reason people seek out direct-to-consumer genetic tests, and for this purpose, the technology works largely as advertised. Companies including AncestryDNA, which led the market with over 25% share in 2024, and 23andMe use single nucleotide polymorphism genotyping to provide genuinely informative breakdowns of geographic ancestry and connect users with genetic relatives. For people interested in family history, genealogy research, or simply curiosity about their heritage, these tests deliver a product that does what it claims to do, within the limits of the reference databases available.
The health-related applications also have real utility in specific, well-defined cases. 23andMe’s Health and Ancestry service is the only direct-to-consumer genetic test that has received FDA approval for certain genetic health risk reports, covering conditions including specific variants associated with breast cancer risk through BRCA1 and BRCA2 genes, certain hereditary conditions, and carrier status for conditions that could affect future children. For someone with a family history of a specific hereditary condition, an at-home test that flags a relevant genetic variant can be the first step toward a conversation with a doctor or genetic counsellor that might not otherwise have happened. Carrier screening for recessive genetic conditions is particularly valuable for couples planning a family, since it can identify whether both partners carry a variant that could affect their children, information that is genuinely actionable.
The broader genomics industry has continued to develop in directions that suggest the underlying technology has long-term value even as individual companies struggle commercially. In March 2025, Tempus AI acquired Ambry Genetics, a genetic testing company that generated over $300 million in revenue in 2024, for approximately $600 million. This acquisition was explicitly framed around integrating AI-driven analytics with genomic data to improve precision medicine. The genetic testing infrastructure that consumer companies built, including reference databases, sequencing pipelines, and consumer-facing interpretation tools, has genuine value to the broader healthcare and pharmaceutical research ecosystem, even if the direct-to-consumer business model that funded its initial development has proved commercially fragile.
The Case Against: Why “False Hope” Is Not Too Strong a Description
The core problem with at-home genetic testing is the gap between what the results say and what consumers understand them to mean. Genetic health risk reports describe probabilistic associations between genetic variants and disease risk, not diagnoses. A report indicating an elevated genetic risk for a condition like type 2 diabetes or heart disease is describing a statistical tendency across populations, heavily mediated by environmental factors, lifestyle, and other genes not captured in the test. For many common conditions, genetics account for a relatively modest proportion of overall risk compared to factors like diet, exercise, smoking, and socioeconomic circumstances. A consumer who receives a report indicating elevated genetic risk for a condition, without the context a genetic counsellor would normally provide, can easily walk away with either unwarranted anxiety or unwarranted reassurance, neither of which reflects what the test actually demonstrated.
Consumer Reports and other independent reviewers have long noted that the picture of disease risk provided by a direct-to-consumer genetic kit can be substantially less complete than what a person would receive through their regular healthcare provider, who considers family history, existing symptoms, and clinical context that a mail-order saliva test cannot capture. The distinction between FDA-approved genetic health risk reports, which exist for a narrow set of conditions and variants, and the much broader “wellness” reports that many companies sell covering everything from caffeine metabolism to muscle composition to sleep quality, is also frequently lost on consumers. The wellness category of reports operates with far less regulatory scrutiny and, in many cases, far less robust scientific backing than the disease risk category.
The privacy and data security dimension of the 23andMe story is not a side issue. It is central to understanding what consumers were actually purchasing. A 2023 data breach exposed the personal information of approximately 7 million users. The company maintained that DNA records themselves were not accessed, but the breach exposed ancestry information, family relationships, and other sensitive data that users had not anticipated could be compromised. The subsequent lawsuits and erosion of trust were significant contributing factors to the company’s financial collapse. When 23andMe’s assets, including its biobank of consumer genetic data covering millions of people, were sold to Regeneron as part of the bankruptcy process, it underscored a reality that few consumers considered when they sent in their saliva sample: the genetic data they submitted became a corporate asset that could be sold, and the company they trusted with the most personal data imaginable could fail financially and pass that data to an entirely different organisation.
The financial collapse of 23andMe is also revealing about the underlying business model. The company’s decline has been attributed to several factors: a decrease in demand for testing kits as the novelty wore off and most enthusiastic early adopters had already tested, significant investments in biotech and telehealth ventures that did not generate returns, and the data breach fallout. The fundamental problem is that genetic testing is largely a one-time purchase. Once someone has their ancestry breakdown and health risk report, there is limited reason to buy another kit. Building a sustainable business on a product that most customers buy exactly once proved difficult, and the company’s pivot toward subscription health services and research partnerships did not generate the recurring revenue needed to sustain the business.
What the Evidence Shows
The evidence suggests a genuinely split picture that depends heavily on what a consumer is seeking and how they interpret the results. For ancestry and genealogy purposes, the tests deliver largely on their promise, and millions of users report genuine satisfaction with this use case. For carrier screening ahead of family planning, and for the narrow set of FDA-approved genetic health risk variants, the tests can surface genuinely actionable information that some consumers would not otherwise encounter.
For the broader category of disease risk and wellness reporting, the evidence supports a more sceptical conclusion. The statistical nature of genetic risk information is poorly communicated to consumers, the gap between direct-to-consumer testing and clinical genetic counselling is significant, and the commercial incentives of testing companies favour expansive, attention-grabbing reports over the more modest and qualified information that the underlying science actually supports. The market itself reflects this: the US direct-to-consumer genetic testing market has actually contracted, from $2.4 billion in 2021 to $1.9 billion in 2024, even as overall awareness and historical usage rates have grown. That contraction suggests that the initial wave of enthusiasm has not translated into the kind of sustained, recurring engagement that would indicate consumers found ongoing value proportional to what they were promised.
The Regeneron acquisition may represent the most honest signal about where genuine value in consumer genetic data lies. Regeneron is a drug development company. Its interest in 23andMe’s biobank is not in continuing to sell ancestry kits to consumers. It is in the aggregate research value of genetic data from millions of people, which can inform drug discovery and precision medicine research. The consumer-facing product may have been, commercially speaking, a customer acquisition mechanism for a research dataset, rather than a sustainable product in its own right.
The Verdict: Useful for Some Purposes, Oversold for Others
At-home genetic testing kits are genuinely useful for ancestry research and for a narrow, FDA-approved category of health risk and carrier screening reports. For these purposes, consumers generally receive what they were promised, and the information can be both interesting and, in the case of carrier screening, genuinely actionable for family planning decisions.
For the much larger category of general health risk and wellness reporting that most consumer genetic testing companies have built their broader product offerings around, the evidence supports describing much of it as selling false hope, or at minimum, selling a level of insight and certainty that the underlying science cannot support. The probabilistic, population-level nature of most genetic risk associations is poorly suited to individual-level decision-making without the context that a healthcare professional would normally provide, and the wellness category in particular often rests on thinner scientific foundations than consumers are led to believe.
The collapse of 23andMe adds a further dimension that consumers considering these tests should weigh seriously: the data you submit is not a one-time transaction that ends when you receive your report. It becomes a corporate asset, subject to the same financial fortunes, acquisitions, and bankruptcies as any other company asset, with consequences for privacy that most consumers never anticipated when they sealed the tube and dropped it in the mail. Anyone considering an at-home genetic test should approach it the way they would approach any other significant medical or financial decision: with realistic expectations about what the result can tell them, an understanding of what happens to their data afterward, and ideally, a conversation with a healthcare provider about how to interpret whatever the report says. The commercial value locked up in genetic data and discoveries also connects to a broader legal question facing the biotechnology sector: whether biotechnology companies should be allowed to patent naturally occurring microbial strains and other biological discoveries, and who ultimately benefits from the commercialisation of biological data and resources.
Leave a Reply